Clinical Trial

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Study acronym: LUNAR-2

Recruiting Phase 3

Summary

This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.

Protocol Amendment History 16 amendments

This ClinicalTrials.gov record has been amended 16 times since 2024-01-10; most recent amendment 2026-06-24.

Status change: Not Yet Recruiting → Recruiting 2024-08-13

Trial Details

NCT Number	NCT06216301
Lead Sponsor	NovoCure GmbH
Conditions	Metastatic Non-small Cell Lung Cancer
Enrollment	734 participants
Start Date	2024-07-31
Primary Completion	2028-10 (estimated)
Study Completion	2028-10 (estimated)
Updated on ClinicalTrials.gov	2026-06-25